Therapeutic focus - Shots on goal could be the key for lung cancer

Date February 10, 2010

Should Novelos Therapeutics’ NOV-002 fail in its phase III trial for non-small cell lung cancer (NSCLC), the results for which are expected soon (Event – Pivotal lung cancer data could see Novelos soar, February 10, 2010) a large number of products are currently lining up to take over the baton in the race to become a new treatment option for this lethal condition. The R&D pipeline for lung cancer is flooded with candidates as big pharma and small biotech alike chase an indication for which a product, if authorised and shown to be better than therapies on the market, is almost certain to be a blockbuster.

A review of product portfolio data from EvaluatePharma indicates that there are 162 candidates in the late-stage pipeline (phase III/phase II) for all lung cancer indications. While natural R&D attrition means that many candidates will drop out having failed to show the efficacy or safety data that regulatory authorities demand, the sheer number of them suggests that some will hit their target and reach the market within the next few years. The entire pipeline from research project to phase III contains 300 candidates, as companies line up a significant number of shots on goal (see tables below).

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd